Literature DB >> 28393404

Patients with high c-MYC-expressing squamous cell carcinomas of the tongue show better survival than those with low- and medium-expressing tumours.

Klas Strindlund1, Giuseppe Troiano2, Nicola Sgaramella3, Philip J Coates4, Xiaolian Gu1, Linda Boldrup1, Luigi Califano5, Robin Fahraeus1,4,6, Lorenzo Lo Muzio2, Fatima Ardito2, Giuseppe Colella3, Gianpaolo Tartaro3, Renato Franco7, Lena Norberg-Spaak8, Mohammad Saadat8, Karin Nylander1.   

Abstract

BACKGROUND: c-MYC is a potent oncoprotein with roles in a wide range of cellular processes such as differentiation, apoptosis and growth control. Deregulation of the MYC gene is commonly seen in human tumours resulting in overexpression of the protein. Here we studied expression of c-MYC in correlation to clinical outcome in patients with primary squamous cell carcinoma of the mobile tongue.
METHODS: Immunohistochemistry was used to identify c-MYC in a group of 104 tongue squamous cell carcinomas with an antibody directed against the N-terminal part of the protein. Staining was evaluated by multiplying the percentage of c-MYC-expressing cells with staining intensity, giving a quick score for each tumour.
RESULTS: All 104 tumours expressed c-MYC at varying levels. Quantitation according to per cent of positive cells and staining intensity revealed that most (15/21; 71%) high-expressing tumours were seen in males. Within the group of high c-MYC-expressing tumours, the majority were alive 2 and 5 years after treatment.
CONCLUSIONS: The present findings show that expression of c-MYC has prognostic value in squamous cell carcinoma of the tongue, and could be useful in choice of therapy.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  c-MYC; radiotherapy; squamous cell carcinoma; tongue

Mesh:

Substances:

Year:  2017        PMID: 28393404     DOI: 10.1111/jop.12579

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  5 in total

1.  Ethnicity based variation in expression of E-cadherin in patients with squamous cell carcinoma of the oral tongue.

Authors:  Nicola Sgaramella; Torben Wilms; Linda Boldrup; Lotta Loljung; Xiaolian Gu; Philip J Coates; Petra Hassellöf; Luigi Califano; Lorenzo Lo Muzio; Robin Fåhraeus; Lena Norberg Spaak; Renato Franco; Gianpaolo Tartaro; Giuseppe Colella; Mario Santagata; Giovanni Dell'Aversana Orabona; Fabrizio Chirico; Karin Danielsson; Giuseppe Troiano; Fatima Ardito; Karin Nylander
Journal:  Oncol Lett       Date:  2018-09-18       Impact factor: 2.967

2.  Bioinformatics-based discovery of PYGM and TNNC2 as potential biomarkers of head and neck squamous cell carcinoma.

Authors:  Yu Jin; Ya Yang
Journal:  Biosci Rep       Date:  2019-07-29       Impact factor: 3.840

3.  Prognostic Value of c-Myc Immunohistochemical Expression in Muscle Invasive Urothelial Carcinoma of the Urinary Bladder: A Retrospective Study.

Authors:  Amira Emad Elwy; Tarek Mohamed Elsaba; Ahmed Refaat Abd Elzaher; Mahmoud Ismail Nassar
Journal:  Asian Pac J Cancer Prev       Date:  2019-12-01

Review 4.  A systematic review and meta-analysis of the prognostic role of age in oral tongue cancer.

Authors:  Marta Tagliabue; Pietro Belloni; Rita De Berardinis; Sara Gandini; Francesco Chu; Stefano Zorzi; Caterina Fumagalli; Luigi Santoro; Susanna Chiocca; Mohssen Ansarin
Journal:  Cancer Med       Date:  2021-03-24       Impact factor: 4.452

5.  Combination therapy with protein kinase inhibitor H89 and Tetrandrine elicits enhanced synergistic antitumor efficacy.

Authors:  Man Yu; Ting Liu; Yicheng Chen; Yafang Li; Wenhua Li
Journal:  J Exp Clin Cancer Res       Date:  2018-06-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.